抗抑郁药
三环
萧条(经济学)
医学
不利影响
三环类抗抑郁药
精神科
单胺氧化酶抑制剂
重症监护医学
单胺氧化酶
药理学
焦虑
生物
宏观经济学
经济
酶
生物化学
出处
期刊:
日期:2024-11-22
卷期号:62 (1): 204-209
被引量:1
标识
DOI:10.54254/2753-8818/62/20241539
摘要
Abstract. Depression is one of the most prevalent mental disorders encountered in clinical practice, with an increasing prevalence year on year, resulting in a significant burden to both individuals and society. The precise aetiology of depression remains uncertain, and the prevailing treatment modality is pharmacological. The clinical use of first-generation antidepressants, such as monoamine oxidase inhibitors and tricyclic antidepressants, is constrained by their adverse effects, including cardiovascular and liver toxicity. Subsequently, a fourth category of antidepressant medications emerged, exhibiting a reduced incidence of adverse effects in comparison to tricyclic antidepressants. The current standard of care for depression employs a range of antidepressant medications, including novel agents. It is important to note that antidepressant drugs have certain side effects and that the pathogenesis of depression remains an area of ongoing investigation. The urgent need for the development of more effective antidepressant drugs with fewer side effects is clear. This article presents a review of the research progress made in the field of antidepressant drugs, to provide a basis for the development of new antidepressant drugs.
科研通智能强力驱动
Strongly Powered by AbleSci AI